Trial Profile
A Randomized Double-Blind, Placebo-Controlled Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men With Prostate Cancer Metastatic to Bone.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 14 Dec 2023
Price :
$35
*
At a glance
- Drugs Zoledronic acid (Primary) ; Antiandrogens
- Indications Bone metastases; Prostate cancer
- Focus Registrational; Therapeutic Use
- 24 Oct 2023 Results comparing treatment regimens androgen deprivation therapy or docetaxel in the control or research arms in mHSPC were utilized from 13 trials which includes (NCT00002651, NCT00216060, NCT00079001, NCT00104715, NCT00268476, NCT00309985, NCT00685646) studies, presented at the 48th European Society for Medical Oncology Congress.
- 13 Sep 2022 Results assessing whether castrate-resistant free survival and time to castrate-resistant disease are valid surrogates for OS from following clinical trials: NCT00002651, NCT00079001, NCT00104715, NCT00268476, NCT00309985, NCT00216060, ISRCTN38477744 and NCT00685646 presented at the 47th European Society for Medical Oncology Congress
- 16 Feb 2013 Results presented at the 2013 Genitourinary Cancers Symposium.